the Efficacy and Safety of Favipiravir for novel coronavirus–infected pneumonia: A multicenter, randomized, open, positive, parallel-controlled clinical study

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000030254

Enrollment

Unknown

Registered

2020-02-26

Start date

2020-02-20

Completion date

Unknown

Last updated

2020-03-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Coronavirus Pneumonia (COVID-19)

Interventions

Experimental group:Farpiravir tablets

Control group:Abidole tablets

Eligibility

Sex/Gender

All

Age

18 Years to 100 Years

Inclusion criteria

Inclusion criteria: (1) Aged 18 years or older; (2) Voluntarily signed informed consent; (3) Hospitalized patients diagnosed as COVID-19.

Exclusion criteria

Exclusion criteria: (1) Allergic to fabiravir or abidol; (2) ALT/AST increased 5 times higher than the upper limit of normal, or with child Pugh C; (3) Severe patients with expected survival time < 48 hours; (4) Pregnancy; (5) HIV positive; (6) Considered unsuitable by researchers.

Design outcomes

Primary

Measure	Time frame
Clinical recovery rate of day 7;	—

Secondary

Measure	Time frame
All-cause mortality during the trial;The rate of respiratory failure during the trial;The time from randomization to fever reduction;The time from randomization to cough relief; The time from randomization to dyspnea relief; The rate of auxiliary oxygen therapy or noninvasive mechanical ventilation during the trial; After one week of treatment, the negative rate of 2019-nCOV RT PCR test for upper respiratory tract specimens; The rate of ICU admission during the trial; Incidence of serious adverse events (SAE) during the trial;	—

Measure

Time frame

All-cause mortality during the trial;The rate of respiratory failure during the trial;The time from randomization to fever reduction;The time from randomization to cough relief; The time from randomization to dyspnea relief; The rate of auxiliary oxygen therapy or noninvasive mechanical ventilation during the trial; After one week of treatment, the negative rate of 2019-nCOV RT PCR test for upper respiratory tract specimens; The rate of ICU admission during the trial; Incidence of serious adverse events (SAE) during the trial;

—

Countries

China

Contacts

Public ContactXinghuan Wang

Zhongnan Hospital of Wuhan University

wangxinghuan@whu.edu.cn+86 027 67813096

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026